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The cancer experience among relatives of an unselected cohort of 402 breast cancer patients was previously reported. Cases
and their ﬁrst degree relatives were ﬂagged at the National Health Service Central Register for continuous notiﬁcation of
cancer registrations and deaths. More than 10 years of follow-up data have been analysed to update cancer risks overall and
to estimate breast cancer risk in relatives prospectively according to family history at the time of breast cancer diagnosis in the
index case. Signiﬁcant excesses of breast cancer (RR 2.24, P50.0001), prostate cancer (RR 1.71, P=0.039) and bone sarcoma
(RR 6.564, P=0.042) overall and soft tissue sarcoma in mothers only (RR 15.44, P=0.001) were found. There was no excess of
any other cancer, including ovarian. High breast cancer risk in relatives was associated with young age at diagnosis in the index
(index 540 years at diagnosis, RR in relatives 3.76, P=0.004). Prospective risk of breast cancer was higher in relatives of index
patients who had an affected ﬁrst degree relative at the time of their diagnosis (no family history, RR 1.87, P=0.012; with a
family history, RR 3.72, P=0.015). These prospective risk estimates are valuable in advising relatives of newly diagnosed breast
cancer patients.
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It has been demonstrated that women with a family history of
breast cancer are at about twice the risk of developing breast cancer
compared with the general population. The magnitude of this risk
may vary according to extent of family history. A recent meta-
analysis incorporating data from 74 publications on familial breast
cancer risk (Pharoah et al, 1997), showed an overall relative risk of
2.1 (95% CI 2.0, 2.2) for breast cancer in a ﬁrst degree relative
associated with a family history of the disease. Risks were also
increased if the age at diagnosis in the index case was less than
50 years (RR=2.4, 95% CI 2.2, 2.7) compared with age 50 years
or more at diagnosis (RR=1.9, 95% CI 1.8, 2.0).
Although three fully-characterised genes associated with high
risk of breast cancer have been identiﬁed; BRCA1, BRCA2 and
TP53 (Ford et al, 1998; Birch et al, 2001), mutations to these genes
account for only part of the excess risk in the relatives of breast
cancer patients. Furthermore, genetic testing for such mutations
is appropriate only in cases meeting certain criteria. However, rela-
tives of breast cancer patients, particularly sisters and daughters,
frequently request information about their risks even in the absence
of any other family history. Few studies are able to provide
unbiased estimates of such risks.
We previously reported on the cancer experience in the families
of an unselected series of breast cancer patients based on inter-
views conducted between 1984 and 1989 (Teare et al, 1994).
These patients and their families have now been followed for
up to 15 years and we report updated overall estimates of cancer
risks and more importantly, prospective breast cancer risks in
relatives taking account of family history at the time of diagnosis
in the index case.
MATERIALS AND METHODS
Ascertainment of cases
Appropriate ethical committee approval for the Study was
obtained. Female patients attending the University Hospital of
South Manchester, for surgery for a primary inﬁltrating carcinoma
of the breast and diagnosed between 1 June 1984 and 31 December
1986 were considered eligible for the study. Of the 474 eligible
cases, 402 (85%) agreed to be interviewed, where detailed informa-
tion on the health status (including cancer experience) of their ﬁrst
and second degree relatives was obtained. Further details of meth-
odology are given by Teare et al (1994). Analysis of cases and their
ﬁrst degree relatives only are presented here.
Conﬁrmation of cancers and follow-up of Cohort
Cancers reported at interview were veriﬁed by obtaining: pathology
reports or other medical records (40.3%) cancer registration details
(43.4%), or death certiﬁcates (11.8%). It was not possible to
conﬁrm reported cancers in nine relatives because they lived
abroad. These relatives were excluded from all analyses. All index
breast cancer patients and their ﬁrst degree relatives were ﬂagged
at the National Health Service Central Register (NHSCR) for
continuous notiﬁcation of cancer registrations and causes of death.
All neoplasms were classiﬁed by International Classiﬁcation of
Diseases for Oncology (ICD-O) (WHO, 1976) morphology code
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Statistical methods
As index breast cancer cases and their ﬁrst degree relatives are
ﬂagged at NHSCR, it is possible to detect cancers that occurred
subsequent to the interview. Expected numbers of cancers were
calculated from calendar period-, sex- and age-speciﬁc cancer rates
for the North West Region supplied by the Ofﬁce for National
Statistics.
A person was considered to be at risk from 1 January 1965
(prior to this cancer registration data were less reliable), or date
of birth (whichever was later) to date of death, 31 August 1999
for ﬂagged relatives, date of last contact for a small number of
unﬂagged relatives, or 75th birthday (whichever was earliest).
In all analyses cancer refers to any malignancy, except for non-
melanoma skin cancer, up to age 75 years but all conﬁrmed pros-
tate cancers were included irrespective of age at diagnosis because
of the late median age at onset and possible relationship to breast
cancer. Multiple primary cancers in the relatives are also included,
along with any tumours of the central nervous system whether or
not malignant.
Relative risks (RR) were calculated by comparing observed
numbers of cancers with expected numbers and two-sided Poisson
probabilities calculated (Breslow and Day, 1987).
For the purpose of the prospective analysis of familial risk of
breast cancer we deﬁned two cohorts of women:
(1) All female ﬁrst degree relatives of index cases having at least
one ﬁrst degree relative (in addition to the index case) with
conﬁrmed breast cancer diagnosed before the index case (at
any time and at any age). These affected ﬁrst degree relatives
were excluded from subsequent analyses of familial risk.
(2) All female ﬁrst degree relatives of index cases with no history
of breast cancer in any ﬁrst degree relative before diagnosis in
the index case.
Observed breast cancers were compared with the expected (as
above) for the two cohorts overall, separately for mothers, daugh-
ters and sisters and categorising them by age at diagnosis in the
index case (550 years, 4=50 years). Observed and expected
numbers of second malignancies in the index cases were also
compared as above. The period of risk was calculated from the date
of diagnosis of breast cancer in the index case. Cancers at all ages
post-diagnosis were considered.
RESULTS
Descriptive data on the 402 cases and their relatives included in the
analyses are presented elsewhere (Teare et al, 1994).
Overall cancer risks
Cancer risks in all ﬁrst degree relatives are presented in Table 1.
For all ﬁrst degree relatives combined for the time period 1965–
1999 there was a signiﬁcant excess of bone sarcomas (based on
two cases), breast cancer and prostate cancer, but no signiﬁcant
excesses or deﬁcits for any other speciﬁc cancer type. The excess
of prostate cancer was attributable to fathers. Signiﬁcant excesses
of breast cancers were seen in mothers, daughters and sisters. In
addition, there was a signiﬁcant excess of soft tissue sarcoma in
mothers based on three cases.
Breast cancer risk by age at diagnosis
Table 2 gives a breakdown of breast cancers in all ﬁrst degree rela-
tives by age at diagnosis in the index case and in the relative.
Young age in the index case (under 50 years) increases the risk
of breast cancer in ﬁrst degree relatives overall, but the effect is
most marked for breast cancers in relatives diagnosed under 40
years of age. There is also a highly signiﬁcant excess of breast
cancers in the relatives of index patients who were diagnosed at
60 years and above. However, there was no signiﬁcant excess of
breast cancers in relatives aged 40–49 years regardless of age at
diagnosis in the index case and no signiﬁcant excesses among rela-
tives of index cases aged 50–59 years at diagnosis. Overall, the
pattern of ages at diagnosis in index patients and their relatives
is complex.
Breast cancer risks by family history of breast cancer
Table 3 gives a breakdown of cancer risk in ﬁrst degree relatives
during the follow-up period after diagnosis of the index case, in
cohorts (1) and (2) described above by type of relative and by
age at diagnosis in the index case (550 years, 4=50 years). These
results represent a prospective assessment of risk taking into
account family history at the time of diagnosis of the index case.
There appears to be a higher subsequent risk of breast cancer in
ﬁrst degree relatives in families with a history of breast cancer prior
to diagnosis in the index case (RR=3.72, P=0.02), compared with
no family history (RR=1.87, P=0.01), but both cohorts show a
signiﬁcant excess. This excess of breast cancer in those with no
prior family history is greater if the index case was diagnosed
before 50 years of age (RR=2.64, P=0.017), compared with age
50 or more (RR=1.55, P=0.17). Prostate cancer and ovarian cancer
risk in ﬁrst degree relatives was also analysed in the two cohorts.
Previous family history of breast cancer did not increase prostate
cancer risk compared with no family history (RR=2.07, P=0.049
with no previous family history; RR=2.22, P=0.44 with a family
history). Although there was no overall excess of ovarian cancer,
it was thought that prior history of breast cancer in a ﬁrst degree
relative in addition to the index case, might confer a higher risk of
ovarian cancer but this was not borne out with only one case of
ovarian cancer in the family history cohort.
Second primary neoplams
There were 24 malignant neoplasms in index cases post-diagnosis
of their original breast cancer compared with 26.55 expected (RR
0.90, P=0.640) These ﬁgures include eight contralateral breast
cancers compared with an expected number of 6.87 (RR 1.16,
P=0.64). Other second cancers included three colon carcinomas,
two carcinoma of vulva, one ovarian carcinoma, four carcinomas
of lung, one carcinoma of larynx, one carcinoma of oesophagus,
one carcinoma of bladder, one lymphoma, one acute myeloid
leukaemia and one multiple myeloma. Younger age at breast cancer
diagnosis in the index case did not appear to be predictive of
increased risk of a second neoplasm with relative risk of 1.12 for
those aged 550 compared with 1.18 for those aged 450 years
at diagnosis. Only two of the eight contralateral breast cancers
occurred in women whose ﬁrst breast cancer was diagnosed under
age 50 years.
DISCUSSION
There have been many studies reporting risks of breast cancer in
the families of breast cancer patients but the present study has a
number of strengths and advantages compared with previous
studies. The series of index patients was completely unselected with
respect to age and although hospital-based it has been demon-
strated that the series is representative of the total population of
breast cancer patients from the same area (Teare et al, 1994). All
cancers reported at interview and included in the analyses were
medically conﬁrmed, and complete data in terms of dates of birth,
diagnosis and death as applicable, were available on ﬁrst degree
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cohort was based on cancer registry data for the same population
from which the cancer patients were drawn. The cancer incidence
data available to us were coded by ICD-O and this allowed us to
employ a cancer morphology based classiﬁcation system, rather
than the usual cancer site-based ﬁgures presented in other studies.
Finally, and most importantly, we were able to estimate relative
risks of breast cancer in ﬁrst degree relatives of the index patients
prospectively following diagnosis in the index patient through the
process of ﬂagging at NHSCR.
Analyses of overall cancer risks incorporating the follow-up
period mainly produced similar relative risks to those reported
previously (Teare et al, 1994) but in addition these updated ﬁgures
demonstrated a signiﬁcant excess of carcinoma of the prostate
particularly in fathers of the index patients. Some of this excess risk
of prostate cancer may be due to mutations in BRCA1 (Ford et al,
1994) and BRCA2 (Breast Cancer Linkage Consortium, 1999). Such
mutations would account for a small proportion of cases only but
the increased risk of prostate cancer in male BRCA1 and BRCA2
mutation carriers indicates some commonality in histogenetic
pathways in breast and prostate carcinomas. Most of the excess
in the present series was due to prostate cancers in fathers of index
patients with no other family history of breast cancer, suggesting
the possibility of shared environmental exposures and/or lower
penetrance mutations.
A previous cohort study of more than 900 breast cancer cases in
Iceland found a relative risk of 1.4 for prostate cancer in their ﬁrst
degree relatives (Tulinius et al, 1992). The 95% conﬁdence interval
included 1.7, the estimated RR in the present study. It should be
noted, however, that among the Icelandic population, the preva-
lence of BRCA2 mutations is about 8% (Arason et al, 1993,
Thorlacius et al, 1996) and this may account for most of the excess
prostate cancer risk in this population. An analysis of cancer
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Table 2 Age at diagnosis of breast cancer in ﬁrst degree relatives by age
at diagnosis in index case
Age at diagnosis
Age in index case at diagnosis
in relative 540 40–49 50–59 60+ Total
54 0 O 1413 9
E 0.1612 0.347 0.539 0.545 1.593
RR 6.203 11.527 1.855 5.505 5.650
P 0.16 0.0005 0.52 0.021 0.0001
4 0 – 4 9 O 1112 5
E 0.469 0.775 1.559 1.823 4.625
RR 2.132 1.290 0.641 1.097 1.081
P 0.46 0.72 0.75 0.82 0.81
50–59 O 4 0 3 9 16
E 0.494 1.178 1.937 2.512 6.122
RR 8.097 – 1.549 3.583 2.614
P 0.002 0.84 0.44 0.002 0.0009
60+ O 1 7 4 8 20
E 0.737 1.802 2.944 4.469 9.951
RR 1.357 3.885 1.359 1.790 2.010
P 0.69 0.003 0.52 0.12 0.0048
Total O 7 12 9 22 50
E 1.861 4.102 6.979 9.349 22.291
RR 3.761 2.925 1.290 2.353 2.243
P 0.004 0.002 0.44 0.0004 50.0001
Table 1 Cancer in ﬁrst degree relatives by site of cancer (excluding nine cases without conﬁrmation of cancer)
Mothers Fathers Sons Daughters Sisters Brothers Total
Cancer (n=238) (n=186) (n=362) (n=364) (n=440) (n=492) (n=2082)
Soft tissue O 3 0 0 0 0 0 3
sarcomas E 0.1943 0.125 0.149 0.159 0.460 0.386 1.474
RR 15.440 2.035
P (0.001) (0.25)
Bone sarcoma O 0 0 1 0 1 0 2
E 0.035 0.043 0.054 0.041 0.047 0.085 0.305
RR 18.587 21.46 6.564
P (0.055) (0.048) (0.042)
Colon/rectum O 1 6 1 0 6 7 21
E 2.948 2.852 0.713 0.568 5.001 6.312 18.394
RR 0.339 2.104 1.403 1.200 1.109 1.142
P (0.097) (0.62) (0.74) (0.53)
Female breast O 14 0 0 9 27 0 50
E 5.011 3.731 13.548 22.29
RR 2.294 2.412 1.993 2.243
P (0.001) (0.02) (0.001) (50.0001)
Ovary O 0 0 0 2 2 0 4
E 1.025 0.483 2.481 3.989
RR 4.141 0.806 1.003
P (0.099) (0.84) (0.93)
Prostate O 0 13 0 0 0 4 17
E 4.532 0.237 5.158 9.927
RR 2.869 0.775 1.713
P (0.001) (0.66) (0.039)
All cancers O 29 40 4 13 57 59 202
a
E 21.146 27.043 6.788 9.984 46.052 53.289 164.3
RR 1.371 1.479 0.589 1.302 1.238 1.107 1.229
P (0.10) (0.003) (0.29) (0.34) (0.12) (0.43) (0.097)
aIn addition to those documented above, ﬁgure includes carcinoma trachea and lung, 33; carcinoma stomach, 10; carcinoma lip/
oral cavity, 9; carcinoma bladder, 7; carcinoma pancreas, 7; carcinoma cervix, 6; CNS tumours, 5; leukaemia/lymphoma, 5;
carcinoma uterus, 3; carcinoma larynx, 2; carcinoma kidney, 2; myeloma, 2; carcinoma liver, 1; adrenocortical carcinoma, 1;
melanoma, 1; teratoma (ovary), 1; other and unspeciﬁed carcinoma, 10.
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breast cancer patients did not ﬁnd excess mortality from prostate
cancer (Peto et al, 1996). That study was weighted to include a
high proportion of cases aged under 40 years at breast cancer diag-
nosis and all cases were aged under 60 years. The present study
includes breast cancer patients of all ages and reports on incident
prostate cancers in their relatives. In this context it is relevant to
note that the prostate cancers occurred in fathers and brothers of
older index cases, all but one being over 50 years at diagnosis of
their breast cancer.
Unexpectedly, there was no indication of any excess risk for
carcinoma of the ovary. Mutations in BRCA1 and BRCA2 both
confer greatly elevated risks for ovarian cancer (Ford et al, 1998).
The lack of excess ovarian cancers suggests that the proportion
of carriers of such mutations among our cohort is likely to be very
small. Similarly, there was no excess of colorectal cancer, although
BRCA1 mutations appear to confer an elevated risk for colon
cancer (Ford et al, 1994). We previously reported a signiﬁcant
excess of sarcomas in the relatives of index patients and this is still
apparent in the series with a signiﬁcant excess of soft tissue sarco-
mas in mothers, and an overall excess of bone sarcoma, although
based on small numbers of cases. Germline mutations in the
TP53 gene are associated with breast cancers, sarcomas and certain
other tumours including adrenocortical carcinoma (Birch et al,
2001). In this context it is of interest that the cohort includes a
case of adrenocortical carcinoma which is exceedingly rare in the
general population.
In common with most previous studies (Pharoah et al, 1997) in
the present series higher risk of breast cancer in ﬁrst degree rela-
tives was associated with younger age at diagnosis in the index
patient. This was not the ﬁnding in a recent large population-based
series also from the UK, where breast cancer risk to mothers and
sisters of index cases was not increased with young age at onset
in the index case (Pharoah et al, 2000). In the latter study only
65% of eligible cases took part compared with 85% in the present
study and breast cancers in their relatives reported by index
patients were not conﬁrmed from medical records. Furthermore,
family histories were obtained by self-completed questionnaires
and missing dates of birth were imputed. There were therefore
potential biases in the data of Pharoah et al (2000). In the present
series information was obtained by in person interview and
complete information on all ﬁrst degree relatives was obtained.
Furthermore, all cancers included in the analysis were medically
conﬁrmed. Therefore the data were not subject to the same biases.
The Collaborative Group on Hormonal Factors in Breast Cancer
(2001) recently reported a meta-analysis of familial breast cancer
among more than 58000 breast cancer cases and more than
100000 controls included in eight cohort studies and 44 case-
control studies. Risk ratio’s were estimated on the basis of numbers
of unconﬁrmed, reported cancers in ﬁrst degree relatives of breast
cancer cases and unaffected controls. It was not possible to esti-
mate breast cancer incidence among ﬁrst degree relatives of cases
and controls since data on attained ages of unaffected, as well as
affected relatives were not consistently available. Therefore,
although the study included very large numbers, there were limita-
tions to the data. Nevertheless, the overall results are compatible
with the present small study which is based on very high quality
data.
The percentages of women with one or more ﬁrst degree rela-
tives with breast cancer are approximately 12 and 10% in the
above meta-analysis and the present study respectively. The slightly
higher ﬁgure in the former is almost certainly due to the younger
median age at diagnosis among patients. The risk ratios for breast
cancer in women with one, two or more than two affected ﬁrst
degree relatives were 1.8, 2.93 and 3.9 respectively in the meta-
analysis. In the present study the estimated prospective relative
risks for breast cancer in women with no previous family history
of breast cancer before the diagnosis in the index case i.e. one
affected ﬁrst degree relative was 1.87. For women with at least
one affected ﬁrst degree relative diagnosed before the index case
i.e. at least two affected relatives in total, the estimated prospective
relative risk was 3.72. Given the very different methodologies in the
two studies, the fact that the risk estimates are so similar is reassur-
ing. However, it should be noted that the relationship between age
at diagnosis in index cases and their relatives and breast cancer risk
in the relatives is not simple. This may be a reﬂection of genetic
heterogeneity and varying penetrance combined with interaction
between genetic and other risk factors.
A unique aspect of the present study is that we were able to
analyse risk of breast cancer in the ﬁrst degree relatives of breast
cancer patients over a follow-up period of more than 10 years in
a prospective fashion, and to consider breast cancer risk in relation
to family history of breast cancer at the time of diagnosis of the
index case. Given the prospective nature of the study and the fact
that the observed and expected cancers derive from exactly the
same source (i.e. cancer registration data through ﬂagging) these
risk estimates are completely free of any bias. The analyses demon-
strated that the breast cancer risk in ﬁrst degree relatives of index
cases, with a previous history of breast cancer, was double that in
the relatives of index cases with no prior family history of breast
cancer. This is an important ﬁnding as this may be masked in
analyses which include only retrospective data on ﬁrst degree rela-
tives (Pharoah et al, 1997). The ﬁgures from our study are much
more in keeping with those of Claus et al (1994) which take into
account more detailed family history. While there was still a signif-
icant excess of breast cancer cases in relatives of index patients with
no previous family history of breast cancer, this excess was greatest
in the relatives of index cases who were aged under 50 years at
diagnosis. Taken together with the ﬁgures presented in Table 2
where greatest risk was seen in relatives of cases diagnosed under
40 years, overall, the results are consistent with recommendations
for moderate risk stratiﬁcation and possible screening only in ﬁrst
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Table 3 Breast cancer risk in female ﬁsrt degree relatives after diagnosis in index case (IC) by family history of breast cancer
No previous family history of breast cancer before
IC Family history of breast cancer before IC
n at risk Observed Expected RR (P) n at risk Observed Expected RR (P)
By type of relative
Mother 110 6 1.61 3.73 (0.01) 2 0 0.044 –
Daughter 304 3 2.52 1.19 (0.71) 51 2 0.42 4.71 (0.08)
Sister 324 10 6.02 1.66 (0.13) 54 3 0.88 3.42 (0.07)
By age at diagnosis in index case
550 years 269 8 3.03 2.64 (0.017) 32 0 0.20 –
50+ 469 11 6.02 1.55 (0.17) 75 5 1.15 4.36 (0.008)
Total 738 19 10.14 1.87 (0.012) 107 5 1.35 3.72 (0.015)
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years of age (Eccles et al, 2000).With respect to second primary
cancers in the index patients occurring during the follow-up peri-
od, there was no overall excess of cancers and perhaps surprisingly,
no signiﬁcant excess of contralateral breast cancer.
Among the cohort of approximately 400 families and including
relatives diagnosed before the index case, there were only 10
families which included three members with conﬁrmed breast
cancer and one family with four conﬁrmed breast cancers (the
index case, one daughter and two sisters). There were 27 families
with two cases including the index case. In our previous descrip-
tion of this cohort (Teare et al, 1994) we observed that the
excess breast cancers were not accounted for by a small number
of high risk families but appeared to be spread across many. Our
conclusions based on more than 10 years of follow-up of these
families remain the same.
It is clear from studies by the Breast Cancer Linkage Consortium
(Ford et al, 1998) that BRCA1 and BRCA2 mutations do not
account for all multi-case breast cancer families. In addition, lower
penetrance mutations and modiﬁer genes may also be involved in
determining risk in breast cancer patients and their families. In the
absence of biological markers, advice to relatives of breast cancer
patients regarding their own risk of breast and other cancers must
rely on statistical estimates of familial risk among series of breast
cancer patients. The present analyses provide unbiased estimates
and will be of use in genetic counselling and clinical management
in breast cancer patients and their families.
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